M3, Inc.

Climate Impact & Sustainability Data (2022, FY2024Q1)

Supported approximately 11 million vaccinations (cumulative orders) for COVID-19.
Supported the development of many vaccines and therapeutics in Japan and overseas.
Utilized “Menkai-kun” at 105 sites, by over 250,000 patients and families for online visitation support during COVID.
Offered physician answers to daily health concerns; 300,000+ posted questions gathering over 75 million UU views annually.
Granted 26 wishes through the CaNoW program for severely ill patients.
Reduced approximately 23.7 million hours of in-office lobby wait-time for patients.

Number of medical consultations using Digikar Smart: 5.6 million per annum, more than 5 times compared to the previous year
Reduction of 1.68 million hours spent in clinics
35.4 million hours of patient waiting time reduced by the M3 group
Offering physician answers online to daily health concerns; ~320,000 posted questions gathering over 79 million UU views annually
44 wishes granted through the CaNoW program; over 1.5 million PVs of videos and articles documenting the grants
Support for corporate health management and employee health promotion; approximately 2 million employees covered

Negative impact of approx. 2 billion yen materialized mainly in the Medical Platform and Evidence Solution segments due to decline in COVID-related sales, with the possibility of larger negative impact for the full year
Lower momentum in order activities. Temporary downtrend due to cyclical factors

Accelerating essential DX initiatives as a strategic partner to pharmaceutical companies
Rejuvenate and strengthen leadership
Continual development of services that dramatically improve the productivity of pharmaceutical company sales and marketing
Continuously expanding the team by several tens of people each year
Standardization of service proposals, skills enhancement, improvement in per-person productivity through DX